NICE Endorses Obecabtagene Autoleucel Therapy f...

By João L. Carapinha

November 25, 2025

NICE Backs Obecabtagene Autoleucel The National Institute for Health and Care Excellence (NICE) recommended obecabtagene autoleucel therapy, a UK-dev...
Rethinking HEOR Market Access Integration: A Call for Early Engagement Before...
Patient-Reported Outcomes Trends in Clinical Trials: Insights from 2008-2023
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Emblaveo MDR Infections: Evaluating a New Solution for Multidrug-Resistant Gr...
Navigating Targeted Therapy Access: Innovations and Challenges in High-Cost T...
Weight Loss: Advances in Hormone-Based Obesity Treatments
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Barriers to African Pharmaceutical Growth: Navigating Regulatory and Procurem...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...